Ionis Pharmaceuticals Inc
NASDAQ:IONS
Ionis Pharmaceuticals Inc
Selling, General & Administrative
Ionis Pharmaceuticals Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Ionis Pharmaceuticals Inc
NASDAQ:IONS
|
Selling, General & Administrative
-$248.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-30%
|
||
Abbvie Inc
NYSE:ABBV
|
Selling, General & Administrative
-$14B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-9%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Selling, General & Administrative
-$5.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-8%
|
||
Amgen Inc
NASDAQ:AMGN
|
Selling, General & Administrative
-$7.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-5%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Selling, General & Administrative
-$1.5B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-17%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Selling, General & Administrative
-$2.9B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-21%
|
Ionis Pharmaceuticals Inc
Glance View
In the realm of pharmaceutical innovation, Ionis Pharmaceuticals Inc. has carved a niche defined by its pioneering efforts in antisense technology. Founded in 1989, Ionis stands as a trailblazer in the development of RNA-targeted therapies, which deviate from the traditional drug development pathways by focusing on genetic solutions. The company specializes in antisense oligonucleotides—short, synthetic strands of DNA or RNA designed to bind selectively to specific messenger RNA (mRNA). By doing so, they aim to modulate the expression of genes associated with various diseases. This unique approach allows Ionis to address ailments at the genetic level, potentially preventing the production of disease-causing proteins, thus offering alternative therapeutic options for serious diseases. Ionis Pharmaceuticals monetizes its scientific breakthroughs through a diverse revenue stream model. It engages in multiple collaborative partnerships with major pharmaceutical companies, such as Biogen and AstraZeneca, which provide upfront payments, milestone-based fees, and royalties on lucrative antisense drugs that emerge from these alliances. Furthermore, Ionis holds an extensive internal pipeline, advancing proprietary drugs through various stages of research and clinical trials. By strategically balancing in-house projects with external collaborations, Ionis capitalizes on its innovative platform while mitigating financial risks. This dual-strategy not only sustains the company financially but positions it at the forefront of personalized medicine, potentially revolutionizing the landscape of therapeutic development.
See Also
What is Ionis Pharmaceuticals Inc's Selling, General & Administrative?
Selling, General & Administrative
-248.4m
USD
Based on the financial report for Sep 30, 2024, Ionis Pharmaceuticals Inc's Selling, General & Administrative amounts to -248.4m USD.
What is Ionis Pharmaceuticals Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-30%
Over the last year, the Selling, General & Administrative growth was -19%. The average annual Selling, General & Administrative growth rates for Ionis Pharmaceuticals Inc have been 5% over the past three years , 2% over the past five years , and -30% over the past ten years .